Market Newsdesk

Mountain View, CA, Nov. 13, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today provided a business update in conjunction with the filing of its Form 10-Q with the Securities and Exchange Commission.

Amro Albanna, Co-Founder and CEO of Aditxt, commented, “It’s been an exciting quarter for Aditxt that started with our successful IPO and Nasdaq listing in early July, followed several weeks later by a successful follow-on public offering. During the quarter we also added well-known industry names to our team and advisory board. Most importantly, we introduced the first application of our AditxtScore™ Monitoring platform, AditxtScore™ for COVID-19, for use in detecting antibodies against SARS-CoV-2 antigens, and for which we are awaiting a response from the U.S. Food and Drug Administration regarding the Emergency Use Authorization (EUA) application that we filed in August. As we’ve announced, we’re working hard to position the Company for commercialization of this product. We believe that Aditxt has accomplished much during its first quarter as a public company, and with cash of $13.7 million at September 30^th to support the execution of our strategy, we are well positioned to achieve our goals for growth.”

For Aditxt’s complete financial results for the period ended September 30, 2020, see the Company’s quarterly report on Form 10-Q that was filed with the Securities and Exchange Commission on November 13, 2020. 

About Aditx Therapeutics

Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in the Company’s prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations:
PCG Advisory
Jeff Ramson
Chief Executive Officer
[email protected]
646-762-4518
www.aditxt.com

Investors with losses are encouraged to contact the firm before December 29, 2020; click


here


to submit trade information

LOS ANGELES, Nov. 13, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Raytheon Technologies Corporation (NYSE: RTX) investors that acquired shares between February 10, 2016 and October 27, 2020. Investors have until December 29, 2020 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

According to the lawsuit, throughout the Class Period the defendants made misleading and/or false statements and/or failed to disclose that: (1) Raytheon had inadequate procedures and disclosure controls and internal control over financial reporting; (2) Raytheon’s financial accounting was faulty; (3) Raytheon misreported its costs regarding Raytheon’s Missiles & Defense business since 2009 as a result; (4) Raytheon was at risk of increased scrutiny from the government as a result of the foregoing; (5) Raytheon would face a criminal investigation by the U.S. Department of Justice (“DOJ”) as a result of the foregoing; and (6) Raytheon’s public statements were materially misleading and/or false at all relevant times, as a result. The lawsuit claims that investors suffered damages when the true details entered the market.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2020.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

INDIANAPOLIS, Nov. 13, 2020 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq Global Select Market: HURC), an international industrial technology company, announced today that its Board of Directors approved the payment of a cash dividend of $0.13 per share on its issued and outstanding common stock. The dividend will be paid on January 20, 2021, to shareholders of record as of the close of business on January 6, 2021.

Future declarations of dividends are subject to approval of the Board of Directors and may be adjusted as business needs or market conditions change.

Hurco Companies, Inc. is an international, industrial technology company that sells its three brands of computer numeric control (“CNC”) machine tools to the worldwide metal cutting and metal forming industry. Two of the Company’s brands of machine tools, Hurco and Milltronics, are equipped with interactive controls that include software that is proprietary to each respective brand. The Company designs these controls and develops the software. The third brand of CNC machine tools, Takumi, is equipped with industrial controls that are produced by third parties, which allows the customer to decide the type of control added to the Takumi CNC machine tool. The Company also produces high-value machine tool components and accessories and provides automation solutions that can be integrated with any machine tool. The end markets for the Company’s products are independent job shops, short-run manufacturing operations within large corporations, and manufacturers with production-oriented operations. The Company’s customers manufacture precision parts, tools, dies, and/or molds for industries such as aerospace, defense, medical equipment, energy, transportation, and computer equipment. The Company is based in Indianapolis, Indiana, with manufacturing operations in Taiwan, Italy, the U.S., and China, and sells its products through direct and indirect sales forces throughout the Americas, Europe, and Asia. The Company has sales, application engineering support and service subsidiaries in China, England, France, Germany, India, Italy, the Netherlands, Poland, Singapore, the U.S., and Taiwan. Web Site: www.hurco.com

Certain statements in this news release are forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These factors include, among others, the cyclical nature of the machine tool industry, changes in general economic and business conditions that affect demand for our products, the risks of our international operations, changes in manufacturing markets, fluctuations in foreign currency exchange rates,
innovations by competitors, increases in prices of raw materials, the ability to protect our intellectual property,
governmental actions and initiatives, including import and export restrictions and tariffs,
breaches of our network and system security measures,
the impact of the COVID-19 pandemic and other public health epidemics on the global economy, our business and operations, our employees, and the business, operations and economies of our customers and vendors,
quality and delivery performance by our vendors, our ability to effectively integrate acquisitions, negative or unforeseen tax consequences
, loss of key personnel, failure to comply with data privacy and security regulations,
and
other risks and uncertainties discussed more fully under the caption “Risk Factors” in our filings with the Securities and
Exchange Commission. We expressly disclaim any obligation to update or revise any forward-looking statements, whether
as a result of
new information, future events or otherwise
.

Contact:	Sonja K. McClelland
	Executive Vice President, Secretary, Treasurer & Chief Financial Officer
	317-293-5309

– Buyer Group led by an affiliate of Cerberus Capital Management, L.P. enters into definitive agreement to purchase all Dorel shares for C$14.50 per share in cash, excluding shares held by Martin Schwartz, Alan Schwartz, Jeffrey Schwartz, Jeff Segel and members of their immediate families

– Definitive agreement with Buyer Group follows independent and thorough evaluation process and negotiations by Special Committee of the Board of Directors of Dorel and provides compelling value to Dorel shareholders

MONTREAL, Nov. 13, 2020 (GLOBE NEWSWIRE) — Dorel Industries Inc. (TSX: DII.B, DII.A) (“Dorel”) today announced that based on the recommendation of an independent committee of Dorel’s Board of Directors (the “Special Committee”), Dorel has entered into a definitive arrangement agreement (the “Arrangement Agreement”) pursuant to which a buyer group (the “Buyer Group”) led by an affiliate of Cerberus Capital Management, L.P. (“Cerberus”) will acquire, for C$14.50 per share in cash, all of Dorel’s issued and outstanding Class A Multiple Voting Shares and Class B Subordinate Voting Shares, except for an aggregate of 4,009,410 Class A Multiple Voting Shares and 2,573,503 Class B Subordinate Voting Shares (the “Rollover Shares”) owned by Martin Schwartz, Alan Schwartz, Jeffrey Schwartz, Jeff Segel and members of their immediate families (collectively, the “Family Shareholders”), by way of a statutory plan of arrangement under the Business Corporations Act (Québec) (the “Arrangement”).

The Board of Directors of Dorel, acting on the unanimous recommendation of the Special Committee, determined that the Arrangement is in the best interests of Dorel and fair to non-Family Shareholders (the “PublicShareholders”), unanimously approved the Arrangement and unanimously recommends that the Public Shareholders vote in favour of the Arrangement at a special meeting of shareholders to be held to approve the Arrangement.

Norman M. Steinberg, Chair of the Special Committee, said, “Today’s announcement is the culmination of a comprehensive process that began in December 2019 when the Family Shareholders informed the Dorel Board of Directors of their intention to initiate a process to find a partner to take Dorel private. Over a period of eleven months, the Special Committee, with the advice of independent financial and legal advisors, has overseen and supervised this process, including contacting more than 25 potential financial sponsor partners, providing diligence materials to such partners, reviewing and considering non-binding proposals submitted by certain of these parties, and negotiating the financial and legal terms of the transaction proposed by the Buyer Group. The Special Committee believes that the Arrangement represents fair value for the Public Shareholders and is the best path forward for Dorel and all of its stakeholders. We are pleased to have been able to reach this agreement with the Buyer Group at a time when Dorel is benefitting from increased demand for its products amid the unique backdrop of 2020.”

Martin Schwartz, President and Chief Executive Officer of Dorel, said “The Family Shareholders believe that the Arrangement is a win for all of Dorel’s stakeholders, including the Public Shareholders. This transaction will enable Dorel to continue to serve our employees, business partners and other stakeholders, and positions Dorel on a path for continued growth.”

“We are very pleased to partner with the Family Shareholders in this transaction,” commented Scott Wille, Senior Managing Director at Cerberus. “Dorel has a long and successful history based on its entrepreneurial culture. We are excited to collaborate with Dorel’s talented and dedicated managers and employees across all three of their business segments to further accelerate growth and enhance each segment’s leadership position.”

The cash consideration to be paid to the Public Shareholders will be financed through a combination of cash funded by the Buyer Group and by Koch Equity Development LLC (“KED”) and committed financing from a group of lenders.

Transaction Highlights and Rationale

In response to the Family Shareholders expressing an interest in exploring a potential privatization transaction, the Board of Directors established the Special Committee, comprised of Norman M. Steinberg (chair), Alain Benedetti, Dian Cohen, Brad A. Johnson, Sharon Ranson and Maurice Tousson, all of whom are independent directors of Dorel.

Dorel, with the help of its financial and legal advisors, designed a process to solicit interest from potential counterparties. Over the past eleven months and under the supervision of the Special Committee, BMO Capital Markets (“BMO”), in its capacity as financial advisor, solicited interest in a potential transaction from a large number of parties. Proposals, including that of Cerberus at C$14.50 per share, were evaluated based on a number of factors.

The Special Committee, after receiving the fairness opinions of BMO and TD Securities Inc. (“TD Securities”), a formal valuation of TD Securities and legal and financial advice, unanimously determined that the Arrangement is fair to the Public Shareholders, recommended that the Board of Directors approve the Arrangement Agreement and recommend that the Public Shareholders vote in favour of the resolution approving the arrangement (the “Arrangement Resolution”) at a special meeting of Dorel shareholders to be called to approve the Arrangement. The Board of Directors, after receiving the fairness opinions of BMO and TD Securities, the formal valuation of TD Securities, legal and financial advice and the recommendation of the Special Committee, unanimously determined, with Martin Schwartz, Alan Schwartz, Jeffrey Schwartz and Jeff Segel abstaining from voting, that the Arrangement is in the best interests of Dorel and is fair to the Public Shareholders, and unanimously recommends, with Martin Schwartz, Alan Schwartz, Jeffrey Schwartz and Jeff Segel abstaining from voting, that the Public Shareholders vote in favour of the Arrangement Resolution.

The conclusions and recommendations of the Special Committee and the Board of Directors are based on a number of factors, including the following:

• Premium to Dorel Trading Price: The purchase price represents a 32% premium to the C$11.02 closing price of Dorel’s Class B Subordinate Voting Shares on the Toronto Stock Exchange (“TSX”) on September 4, 2020, the date on which the Family Shareholders granted exclusivity to Cerberus, and for the periods ended October 30, 2020, a 19% premium to the 60-day volume weighted average trading price (“VWAP”) and a 7% premium to the 30-day VWAP of Dorel’s Class B Subordinate Voting Shares on the TSX.
• Certainty of Value and Liquidity: The payment to the Public Shareholders under the terms of the Arrangement Agreement will be all cash, which provides certainty and immediate liquidity. By contrast, Dorel has historically experienced limited trading liquidity, which makes it difficult for existing Public Shareholders to realize meaningful liquidity through the public markets on which the shares trade.
• Value Supported by a Formal Valuation and Two Fairness Opinions: The Special Committee received a fairness opinion and independent formal valuation of Dorel’s shares from TD Securities as well as a fairness opinion from BMO. The purchase price of C$14.50 per share is within the range of fair market value for the shares of C$14.00 to C$17.00 per share as of November 12, 2020, as set out in TD Securities’ written valuation report pursuant to Multilateral Instrument 61-101Protection of Minority Security Holders in Special Transactions (“MI 61-101”), and subject to the assumptions, limitations and qualifications included therein.
• Procedural Safeguards for Minority Shareholders: The Arrangement was negotiated by the Special Committee, which is comprised solely of directors who are unrelated to the Family Shareholders and management, and which was advised by experienced, qualified and independent financial and legal advisors. The Arrangement will become effective only if it is approved by (i) at least 66 ^2/3% of the votes cast by shareholders at a special meeting of shareholders called to consider the Arrangement; (ii) a simple majority of the votes cast by shareholders, excluding for this purpose the votes attached to Rollover Shares and other Class A Multiple Voting Shares pursuant to MI 61-101, and (iii) the Superior Court of Québec, after considering the procedural and substantive fairness of the Arrangement.
• Attractive Transaction Relative to Status Quo: The Special Committee, with the assistance of its financial and legal advisors, and based upon its collective knowledge of the business, affairs, operations, assets, liabilities, financial condition, results of operations and prospects of Dorel and the current and prospective environment in which Dorel operates (including global tariffs and the current global economic and market conditions, notably in the context of the COVID-19 pandemic), believes that the Arrangement is an attractive proposition for shareholders relative to the status quo.
• Challenges Presented by Operational, Financial and Share Price Performance: Dorel’s public stock trades at a notable discount to its peers and historical trading levels. The share price has declined notably over the last five years, with a share price decrease of approximately 53% for a variety of reasons, including concerns about global tariffs, the COVID-19 pandemic, Dorel’s volatile margins and financial situation as well as its mixed track record of delivering on an operational and financial level. The Special Committee believes that this dynamic is likely to continue, rendering the all-cash consideration offered by the Buyer Group attractive for the Public Shareholders.
• Extensive Process: BMO conducted a comprehensive process, contacting more than 25 potential financial sponsor partners over a period of eleven months leading up to the Arrangement. The Arrangement Agreement is the result of extensive arm’s-length negotiations between Dorel and Cerberus, with the oversight and participation of the Special Committee, which received independent legal and financial advice throughout the process; the purchase price of C$14.50 per share represents the highest proposal received as part of the process.
• Ability to Respond to Superior Proposal: Under the Arrangement Agreement, the Board of Directors, in certain circumstances until shareholder approval is obtained, is able to consider, accept and enter into a definitive agreement with respect to a superior proposal, or withdraw, modify or amend its recommendation that shareholders vote to approve the Arrangement Agreement. In addition, Dorel’s independent directors have entered into customary voting and support agreements with the Buyer Group that provide the ability to vote for, support or participate in a superior proposal. In the view of the Special Committee, none of the break fees potentially payable under the Arrangement Agreement would preclude a third party from making a superior proposal. However, the limitations contained in the voting and support agreements executed by the Family Shareholders in favour of Cerberus restrict the ability to vote for, support or participate in a superior proposal. This may discourage other parties from offering to acquire Dorel’s shares.
• Arm’s Length Negotiations and Oversight: The Arrangement Agreement is the result of robust, arm’s-length negotiations between Dorel and the Buyer Group. Extensive financial, legal and other advice was provided to the Special Committee and the Board of Directors. This advice included detailed financial advice from highly-qualified financial advisors, including with respect to remaining an independent publicly-traded company and continuing to pursue Dorel’s business plan on a stand-alone basis as well as a formal valuation of the shares.
• Limited Conditions to Closing: The Buyer Group’s obligation to complete the Arrangement is subject to a limited number of customary conditions that the Special Committee believes are reasonable in the circumstances. The completion of the Arrangement is not subject to any financing condition.
• Family Shareholders’ Intentions: The Family Shareholders have advised the Special Committee that they are not interested in any alternative transaction, including the sale of their interests in Dorel or the sale of any of Dorel’s businesses segments or material assets.

Fairness Opinions and Independent Valuation

In connection with its review, Dorel retained BMO as financial advisor and the Special Committee retained TD Securities as independent financial advisor and independent valuator. BMO and TD Securities each provided an opinion that, as at November 12, 2020, subject to the assumptions, limitations and qualifications contained therein, the consideration to be received by the Public Shareholders pursuant to the Arrangement is fair to such shareholders from a financial point of view. TD Securities also provided the Special Committee with a formal valuation that was completed under the supervision of the Special Committee. The formal valuation, dated as of November 12, 2020, determined that as at November 12, 2020, subject to the assumptions, limitations and qualifications contained therein, the fair market value of Dorel’s shares ranged from C$14.00 to C$17.00 per share. The fairness opinions and formal valuation will be included in the management information circular to be filed and distributed to Dorel shareholders in connection with the special meeting.

Transaction Details

The Arrangement will be implemented by way of a statutory plan of arrangement under the Business Corporations Act (Québec) and is subject to approval by the Québec Superior Court. Implementation of the Arrangement will also be subject to approval of the Arrangement Resolution by at least 66 ^2/3% of the votes cast by Dorel shareholders present in person or represented by proxy at the special meeting, voting as a single class, and to approval of the Arrangement Resolution by a simple majority of the votes cast by holders of Class B Subordinate Voting Shares in person or represented by proxy at the special meeting, excluding the Rollover Shares held by the Family Shareholders and their respective affiliates. Under Canadian securities regulations, holders of Class A Multiple Voting Shares will not participate in the “majority of the minority” vote as the Family Shareholders own in the aggregate more than 90% of the Class A Multiple Voting Shares. Further details regarding the applicable voting requirements will be contained in Dorel’s management information circular to be prepared in connection with the special meeting.

The Arrangement Agreement includes customary provisions relating to non-solicitation, subject to customary “fiduciary out” provisions that entitle Dorel to consider and accept a superior proposal if the purchaser does not match the superior proposal. A termination fee of approximately C$14.1 million will be payable by Dorel to the purchaser in certain circumstances, including if the purchaser fails to exercise its right to match in the context of a superior proposal supported by Dorel. The purchaser has agreed to pay Dorel a termination fee of approximately C$23.6 million if the Arrangement is not completed in certain circumstances. The Arrangement is subject to customary closing conditions, including receipt of regulatory approvals, and is expected to close early in 2021.

Dorel intends to hold the special meeting of shareholders in January 2021. In light of ongoing public health concerns related to the COVID-19 pandemic and in order to comply with government decrees, the special meeting will be held in virtual-only format, conducted via live webcast. Shareholders will be able to participate and vote at the meeting online regardless of their geographic location. Additional details regarding the terms and conditions of the Arrangement, the rationale for the recommendations made by the Special Committee and the Board of Directors, and how shareholders can participate in and vote at the virtual meeting, will be set out in Dorel’s management information circular. The circular and the Arrangement Agreement will be available under Dorel’s profile at www.sedar.com.

The Family Shareholders will remain shareholders of Dorel following closing of the Arrangement. Martin Schwartz, Alan Schwartz, Jeffrey Schwartz and Jeff Segel are executive officers and directors of Dorel. The Rollover Shares represent 95.7% of Dorel’s 4,188,375 issued and outstanding Class A Multiple Voting Shares and 9.1% of its 28,316,946 issued and outstanding Class B Subordinate Voting Shares.

Early Warning Disclosure by the Family Shareholders

Further to the requirements of National Instrument 62-104 Take-Over Bids and Issuer Bids and National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, the Family Shareholders will file an early warning report stipulating that together with Cerberus, they intend to acquire, directly or indirectly, all of Dorel’s issued and outstanding shares other than the Rollover Shares by way of a plan of arrangement and for which they have entered into irrevocable voting support agreements pursuant to which they have agreed to support, and vote all of their Dorel shares in favour of, the Arrangement Resolution and against any resolution submitted by any shareholder that is inconsistent therewith. A copy of the Family Shareholders’ early warning report will be filed with the applicable securities commissions and will be made available on SEDAR at www.sedar.com. Further information may be obtained by contacting Mr. Jeffrey Schwartz, Executive Vice-President, Chief Financial Officer and Secretary of Dorel, at 514 934-3034.

Advisors

BMO is acting as the financial advisor to Dorel and TD Securities has been retained by the Special Committee as independent financial advisor and independent valuator in accordance with applicable securities laws. McCarthy Tétrault LLP acts as independent legal counsel to the Special Committee and Fasken Martineau DuMoulin LLP acts as legal counsel to Dorel.

Rothschild & Co is acting as financial advisor, Houlihan Lokey Capital, Inc. is acting as placement agent, while Kirkland & Ellis LLP and Blake, Cassels & Graydon LLP are acting as legal counsel to Cerberus. Davies Ward Phillips & Vineberg LLP is acting as legal counsel to the Family Shareholders. Osler, Hoskin & Harcourt LLP is acting as legal counsel to KED.

About Dorel Industries Inc.

Dorel Industries Inc. (TSX: DII.B, DII.A) is a global organization, operating three distinct businesses in juvenile products, bicycles and home products. Dorel’s strength lies in the diversity, innovation and quality of its products as well as the superiority of its brands. Dorel Juvenile’s powerfully branded products include global brands Maxi-Cosi, Quinny and Tiny Love, complemented by regional brands such as Safety 1^st, Bébé Confort, Cosco and Infanti. Dorel Sports brands include Cannondale, Schwinn, GT, Mongoose, Caloi and IronHorse. Dorel Home, with its comprehensive e-commerce platform, markets a wide assortment of domestically produced and imported furniture. Dorel has annual sales of US $2.6 billion and employs approximately 8,000 people in facilities located in 25 countries worldwide.

About Cerberus

Founded in 1992, Cerberus is a global leader in alternative investing with over $48 billion in assets across complementary credit, private equity, and real estate strategies. We invest across the capital structure where our integrated investment platforms and proprietary operating capabilities create an edge to improve performance and drive long-term value. Our tenured teams have experience working collaboratively across asset classes, sectors, and geographies to seek strong risk-adjusted returns for our investors. For more information about our people and platforms, visit us at www.cerberus.com.

About Koch Equity Development

KED is the acquisition and investment subsidiary of Koch Industries, Inc. and focuses its efforts on traditional merger and acquisition activity, as well as principal investments. Since 2012, KED has invested approximately US$30 billion of equity capital into public, private and family-owned businesses.

Caution Regarding Forward-Looking Statements

Certain statements included in this press release may constitute “forward-looking statements” within the meaning of applicable Canadian securities legislation. More particularly and without limitation, this press release contains forward-looking statements and information regarding the anticipated benefits of the proposed Arrangement for Dorel, its employees, business partners, shareholders and other stakeholders, including future financial and operating results, plans, objectives, expectations and intentions of Cerberus, the Buyer Group or Dorel, and the anticipated timing of the special meeting of Dorel shareholders and of the completion of the proposed Arrangement. Except as may be required by Canadian securities laws, Dorel does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements, by their very nature, are subject to numerous risks and uncertainties and are based on several assumptions which give rise to the possibility that actual results could differ materially from Dorel’s expectations expressed in or implied by such forward-looking statements and that the objectives, plans, strategic priorities and business outlook may not be achieved. As a result, Dorel cannot guarantee that any forward-looking statements will materialize, or if any of them do, what benefits Dorel will derive from them.

In respect of forward-looking statements and information concerning the anticipated benefits and timing of the completion of the proposed Arrangement, Dorel has provided such statements and information in reliance on certain assumptions that it believes are reasonable at this time, including assumptions as to the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholder approvals; the ability of the parties to satisfy, in a timely manner, the other conditions for the completion of the Arrangement, and other expectations and assumptions concerning the proposed Arrangement. The anticipated dates indicated may change for a number of reasons, including the inability to receive, in a timely manner, the necessary regulatory, court and shareholder approvals, the necessity to extend the time limits for satisfying the other conditions for the completion of the proposed Arrangement or the ability of the Board of Directors to consider and approve, subject to compliance by Dorel of its obligations under the Arrangement Agreement, a superior proposal for Dorel. Although Dorel believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct, that the proposed Arrangement will be completed or that it will be completed on the terms and conditions contemplated in this press release. Accordingly, investors and others are cautioned that undue reliance should not be placed on any forward-looking statements.

Risks and uncertainties inherent in the nature of the proposed Arrangement include, without limitation, the failure of the parties to obtain the necessary shareholder, regulatory and court approvals or to otherwise satisfy the conditions for the completion of the Arrangement; failure of the parties to obtain such approvals or satisfy such conditions in a timely manner; significant transaction costs or unknown liabilities; the ability of the Board of Directors to consider and approve, subject to compliance by Dorel with its obligations under the Arrangement Agreement, a superior proposal for Dorel; the failure to realize the expected benefits of the Arrangement; and general economic conditions. Failure to obtain the necessary shareholder, regulatory and court approvals, or the failure of the parties to otherwise satisfy the conditions for the completion of the Arrangement or to complete the Arrangement, may result in the Arrangement not being completed on the proposed terms or at all. In addition, if the Arrangement is not completed, and Dorel continues as an independent entity, there are risks that the announcement of the proposed Arrangement and the dedication of substantial resources by Dorel to the completion of the Arrangement could have an impact on its business and strategic relationships, including with future and prospective employees, customers, suppliers and partners, operating results and activities in general, and could have a material adverse effect on its current and future operations, financial condition and prospects. Furthermore, the failure by Dorel to comply with the terms of the Arrangement Agreement may, in certain circumstances, result in it being required to pay a fee to the Buyer Group, the result of which could have a material adverse effect on its financial position and results of operations and its ability to fund growth prospects and current operations. Consequently, Dorel cautions readers not to place undue reliance on the forward-looking statements and information contained in this press release.

No Offer or Solicitation

This announcement is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell Dorel shares.

 

CONTACT
S
:

Saint Victor Investments Inc
Rick Leckner
(514) 245-9232

Cerberus
Jason Ghassemi
Chief Communications Officer
[email protected]

 

– Findings support upcoming launch of T-Detect
™
COVID
,
first
T-
cell
test for novel coronavirus

– Data support mounting evidence that
measuring
T-
cell
s
is
necessary
to
fully
characteriz
e
immune responses
to SARS-CoV-2
across the population

– Additional
supporting
data
to be
published
soon

SEATTLE, Nov. 13, 2020 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its T-Detect™ Assay for past SARS-CoV-2 infection in development identified 97% (68/70) of past PCR-confirmed SARS-CoV-2 infections compared to 77% (54/70) with commercial EUA approved antibody testing at similar specificity approximately two months after PCR diagnosis. Additionally, the T-cell response was greater in symptomatic versus asymptomatic subjects, whereas there was no correlation between antibody levels and disease severity in recovered patients. Preliminary results of this study, performed in collaboration with University of Padua and Ospedale San Raffaele in Milan, who were funded by a grant from Umberto Veronesi Foundation were made available on medRxiv. T-Detect™ COVID will be launched later this fall, becoming the first clinical T-cell based diagnostic test able to confirm past infections to SARS-CoV-2.

It is likely that some people may never develop antibodies to SARS-CoV-2 because they can resolve the infection early and effectively with T cells. Recent studies have demonstrated that antibodies appear to wane over time¹, while virus-specific T cells have been shown to persist for at least six months². This new study adds to mounting evidence that T cells, along with antibodies, may serve as an important correlate of immune protection and can help provide a more complete picture of the duration of immunity to the virus following an infection or administration of a vaccine.

“These data add to the growing body of real-world evidence that the T cell plays a critical role in immunity to SARS-CoV-2,” said Lance Baldo, Chief Medical Officer of Adaptive Biotechnologies. “T cells are emerging as another key indicator for past infection and immunity to the novel coronavirus, and a T-cell test for patients that is accurate and reproducible can serve large populations of people given what we are learning about the biology of the immune response.”

An initial study published in Nature in June 2020 was conducted by the University of Padua in which nearly the entire population of Vo’, Italy (2,900 of the town’s 3,275 residents), was tested using PCR for SARS-CoV-2 infection at the beginning and end of a 14-day lockdown of the town, followed by longer-term clinical monitoring. At that time, 81 people in the town tested positive for the virus in at least one of the two surveys. Interestingly, more than 40% of those who tested positive were asymptomatic, guiding the town’s response to the then-emerging pandemic and driving their success in containment³.

In a follow-up study of 2,290 residents, including 70 of the 81 who tested positive by PCR, antibody testing with a EUA approved commercial test (IgG) and T-cell testing with Adaptive’s T-Detect Assay for past SARS-CoV-2 infection were performed approximately 60 days after PCR testing. The T-cell assay identified 97% (68/70) of past PCR-confirmed SARS-CoV-2 infections compared to 77% (54/70) with the antibody test. Notably, 24 of the 70 PCR -positive patients were asymptomatic, highlighting the added sensitivity of T-cell based testing to provide a more accurate representation of past infection in a community. The T-cell response was measured by the overall quantity of T cells as well as the number of unique virus-specific T cells. Convalescent subjects who were symptomatic and hospitalized with COVID-19 had significantly greater T-cell response than asymptomatic subjects, while antibody levels did not correlate with disease severity.

Notably, an additional 45 (2.0%) of PCR-negative participants tested positive with the T-Detect Assay for past SARS-CoV-2 infection. About half of these individuals had reported symptoms before or after PCR testing or a household exposure, indicating the T-cell assay may also identify past infections that had been missed by prior PCR testing.

About T-Detect
™

T-Detect™ is a highly sensitive and specific diagnostic test under development for multiple diseases, translating the natural diagnostic capability of T cells into clinical practice. In 2018, Adaptive and Microsoft partnered to build a map of the immune system called the TCR-Antigen Map. This approach uses immunosequencing, proprietary computational modeling, and machine learning to map T-cell receptor sequences to disease-associated antigens for infectious diseases, autoimmune disorders and cancer. From a simple blood draw, T-Detect will leverage the map to provide an immunostatus for an individual, enabling early disease diagnosis, disease monitoring, and critical insights into immunity. T-Detect COVID will be the first clinical test launched from this collaboration and the first commercially available T cell test designed to detect past SARS-CoV-2 infections. It is expected to launch this fall.

About Adaptive
Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.

Forward Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including statements regarding T-Detect™ and its launch, potential commercial acceptance, or clinical utility, either with respect to COVID-19 or other disease states. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time, including a Quarterly Report on Form 10-Q to be filed later today. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

ADAPTIVE MEDIA

Beth Keshishian
917-912-7195
[email protected]

ADAPTIVE INVESTORS

Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
[email protected]

^{___________________________________}
¹ Ward, et al.medRxiV preprint, 2020 
² Zuo, et al. bioRxiV preprint, 2020
³ Lavezzo, et al. Nature, 2020​

Investors with losses of more than $1,000,000 are encouraged to contact the firm before November 23, 2020; click 


here


to submit trade information

​LOS ANGELES, Nov. 13, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Wrap Technologies, Inc. (NASDAQ: WRTC) investors that acquired shares between July 31, 2020 and September 23, 2020. Investors have until November 23, 2020 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in this lawsuit that, throughout the class period, defendants made misleading and/or false statements and/or failed to disclose that: (1) Wrap had concealed the results of the LAPD BolaWrap pilot program, which had demonstrated that the BolaWrap was expensive, sparingly used in the field, and ineffective; and (2) Wrap’s public statements were materially false and/or misleading at all relevant times, as a result. The lawsuit claims that investors suffered damages when the true details entered the market.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 23, 2020.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that management will be participating in two upcoming virtual investor conferences and invites investors to participate by webcast. Please see additional details below:

• Jefferies 2020 Virtual London Healthcare Conference, November 17-19,2020
  Management will deliver a company presentation on Thursday, November 19 at 10:50 a.m. ET (3:50 p.m. GMT) and will also be available for one-on-one meetings. A live and archived webcast of the presentation will be available on the Investors section of the Aligos website: https://investor.aligos.com

• Piper Sandler 32
  
  ^nd
  
   Annual Virtual Healthcare Conference, December 1-3, 2020
  Management will present in a fireside chat format and will be available for one-on-one meetings. The presentations will be available prior to the dates of the conference. A replay of the fireside chat will be available in the Investors section of the Aligos website: https://investor.aligos.com

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Please visit www.aligos.com for more information.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos’s clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’s prospectus filed with the Securities and Exchange Commission on October 19, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Media Contact

Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
[email protected]

Investor Contact

Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]

FALLS CHURCH, Va., Nov. 13, 2020 (GLOBE NEWSWIRE) — PAE (NASDAQ: PAE, PAEWW), a global leader in delivering smart solutions to the U.S. government and its allies, was awarded a position on the U.S. Air Force Rotary Wing Maintenance Contract Consolidation indefinite delivery, indefinite quantity contract vehicle, which has a ceiling value of $835 million and a 10-year period of performance. The Air Force Installation Contracting Center also awarded PAE an initial five-year task order on the contract, valued at $84.3 million, to support helicopter maintenance for training missions with the Air Education and Training Command at Kirtland Air Force Base in Albuquerque, New Mexico.

The awards build on PAE’s nearly four decades of aviation support for U.S. government customers, including four branches of the military and the Department of Homeland Security. PAE President and CEO John Heller said this work supporting critical Air Force missions contributes to a business strategy of delivering world class aerospace services through innovation and technology integration.

“PAE’s specialized fleet management expertise is a clear advantage to winning key Air Force support work, strengthened by our certified continuous improvement practices,” Heller said. “Not only does our position on this IDIQ expand our reach with the Air Force, but it brings the potential to apply our rotary wing capabilities to the latest technologies, including the newly acquired MH-139 helicopter.”

PAE is one of five large business contractors awarded a seat on the contract vehicle that also includes three small business awardees. The program consolidates Air Force helicopter programs for the full-time availability of mission-capable aircraft, including UH-1N and HH-60 helicopters and V-22 tilt-rotor aircraft. The scope of the contract includes functional check flights, aircrew flight equipment and the maintenance of light caliber weapons and defensive systems.

PAE Vice President of Readiness and Sustainment Cristal Rice said PAE will deliver mission-essential services on the initial task order for the Air Force’s premier training site for special operations, combat search and rescue aircrews.

“We’re proud to continue our work with the AETC program to provide safe and high-quality aircraft maintenance,” said Rice. “Our services are critical to student pilots as they’re trained on a wide range of flight specialties in aircraft that we maintain for the 58^th Special Operations Wing.”

PAE serves as the prime contractor on the task order, with support from subcontractors CLX Support Services and VP KIRA, to deliver personnel to maintain, repair and functionally check helicopters and associated engines, as well as provide mission support equipment, technical support and aircrew services in support of flight crew training missions at Kirtland Air Force Base.

About PAE

For 65 years, PAE has tackled the world’s toughest challenges to deliver agile and steadfast solutions to the U.S. government and its allies. With a global workforce of about 20,000 on all seven continents and in approximately 60 countries, PAE delivers a broad range of operational support services to meet the critical needs of our clients. Our headquarters is in Falls Church, Virginia. Find us online at pae.com, on Facebook, Twitter and LinkedIn.

Forward-Looking Statements

This release may contain a number of “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about PAE’s possible or assumed future results of operations, financial results, backlog, estimation of resources for contracts, strategy for and management of growth, needs for additional capital, risks related to U.S. government contracting generally, including congressional approval of appropriations, bid protests and IDIQs. These forward-looking statements are based on PAE’s management’s current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside PAE’s management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

Forward-looking statements included in this release speak only as of the date of this release. PAE does not undertake any obligation to update its forward-looking statements to reflect events or circumstances after the date of this release except as may be required by the federal securities laws.

For media inquiries regarding PAE, contact:

Terrence Nowlin
Senior Communications Manager
PAE
703-656-7423
[email protected]

For investor inquiries regarding PAE, contact:

Mark Zindler
Vice President, Investor Relations
PAE
703-717-6017
[email protected]

 

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

HAMILTON, Ontario, Nov. 13, 2020 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTCQB:RQHTF) (“Reliq” or the “Company”), a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community-Based Healthcare, is pleased to announce that it has closed the first tranche of its private placement announced October 27, 2020. The Company issued 10,637,056 units (the “Units”) at a price of $0.225 per unit for gross proceeds of $2,393,337.60 for the first tranche.

Due to exceptional demand, the Company intends to close a second tranche, with final closing taking place on or before December 7, 2020. Pursuant to a price reservation form 4A filed with the TSX-V Venture Exchange on October 22, 2020, the Company may offer up to an additional 2,696,277 Units in a second tranche.

Each Unit will consist of one (1) common share and one-half (1/2) of a share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable for an additional share at a price of $0.30 for a period of two (2) years from issuance. In the event that the common shares of the Company trade at a closing price of greater than $0.50 per Share for ten (10) consecutive trading days, the Company may accelerate the expiry date of the Warrants to expire on the 30th day after the date on which such notice is given to the warrantholders.

The Company is paying finder’s fees of $44,431.88 cash and 188,775 broker warrants in connection with the first tranche. The broker warrants are issued with the same terms as the Warrants described above.

The Company’s CEO participated in the first tranche of the Offering and will acquire an aggregate of 444,500 Units. The participation by insiders in the Offering is considered to be a “related party transaction” as defined under Multilateral Instrument 61-101 (“MI 61- 101”). The transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101, as neither the fair market value of the securities being issued nor the consideration being paid exceeds 25% of the Company’s market capitalization.

The Company intends to use the net proceeds to support onboarding of new clients. All securities issued pursuant to the offering will be subject to a statutory hold period of four months plus a day from issuance in accordance with applicable securities laws. Closing of the Offering is subject to receipt of all necessary regulatory approvals and final acceptance by the TSX Venture Exchange.

About Reliq Health
Reliq Health Technologies is a healthcare technology company that specializes in developing innovative software solutions for the Community Care market. Reliq’s powerful iUGO Care platform supports care coordination and community-based healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT and on the OTCQB as RQHTF.

ON BEHALF OF THE BOARD

“Dr. Lisa Crossley”

CEO and Director

For further information please contact:

Investor Relations at [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the “Company“) does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Reliq Health Technologies Inc.